Commentary
Oncostatin M is a pleiotropic cytokine of the interleukin (IL)-6 family that contributes to the progression of chronic liver disease.
G. Di Maira et al. (University of Firenze, Italy) aimed to investigate the role of oncostatin M in the development and progression of hepatocellular carcinoma in NAFLD/NASH.
In a murine model of NAFLD/NASH-related hepatocarcinogenesis, and in analysis of liver specimens from human NASH-related HCCs with vascular invasion, oncostatin M up-regulation appears to be a specific feature of HCC arising on a NAFLD/NASH background, and it correlates with clinical parameters and disease outcome. For the authors, these data highlight a novel pro-carcinogenic contribution for oncostatin M in NAFLD/NASH.
